OncoPharm

John Bossaer

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

  1. Breast Cancer Updates and T-Cell Stemness

    -5 j

    Breast Cancer Updates and T-Cell Stemness

    This week we discuss a new approval for pabociclib in HER2-positive disease based on the PATINA trial as well as the use of sacituzumab govitecan + pembrolizumab in TNBC, recently approved based on the ASCENT04/KEYNOTED19 trial. And the concept of T-cell "stemless" is intriguing with possibilities: DOI: 10.1056/NEJMcibr2601002 Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

    19 min
  2. Updates on capivasertib, belzutifan, talquetamab, & durvalumab

    18 juin

    Updates on capivasertib, belzutifan, talquetamab, & durvalumab

    Lots of bite-size updates in this episode. Capitello-281: capivasertib + abiraterone (+ prednisone + ADT) Adjuvant Belzutifan + Pemroblizumab is FDA approved Durvalumab approved with BCG for non-muscle invasive bladder cancer Insightful commentary: https://doi.org/10.1200/JCO-25-02670 Talquetamab + Durvaluamb - a new safety signal? Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

    20 min
  3. ASCO '26

    11 juin

    ASCO '26

    ASCO 2026 is a wrap, and we needed an extra week to digest it all! Here the review list: 1. RASolute 302 - daraxonrasib and its standing ovation 2. MajesTEC-9 - 2L teclistamab in multiple myeloma in patient population 100% exposed to CD-38 targeting drugs 3. Initsmeran autogene + pembrolizumab in resected melanoma. Only a Phase 2 study, but super promising and exciting use of personalized medicine using mRNA technology 4. Libretto-043 - adjuvant selpercatinib in RET-fusion positive NSCLC following resection and platinum-based chemotherapy (in most of these patients) 5. PROTEUS - meh 6. SARC041 - Phase study of abemaciclib vs. placebo in dedifferntiated liposarcoma. The placebo did very poorly 7. CROWN at 7-years continues to offer an enticing PFS plateau with lorlatinib use in advanced ALK rearrangement+ NSCLC The Learning Oncology Companion from KelleyCPharmD: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

    26 min
  4. Pivekimab sunirine

    28 mai

    Pivekimab sunirine

    Pivekimab sunirine, a novel CD-123 antibody drug conjugate is approved for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Also, what the heck is BPDCN? Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

    14 min
  5. BCL2 & HER2 Targeting Agent Updates

    21 mai

    BCL2 & HER2 Targeting Agent Updates

    The FDA has been a bunch of busy bees with new approvals: 1. Sonrotoclax, an exciting new BCL2 inhibitor approved for 3rd-line Mantle Cell Lymphoma 2. An all PO regimen of decitabine/cedazuridine + venetoclax is approved for AML. 3. Zenoctuzumab gets an FDA approval for cholangiocarcinoma with an efficacy patient population = 19 4. T-DXd is a good drug and continues to pile on FDA approvals 5. Adjuvant atezolizumab in bladder cancer is approved in conjunction with ctDNA serial monitoring to determine who gets treatment Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

    14 min
  6. IMHOTEP, PJP, and more

    14 mai

    IMHOTEP, PJP, and more

    This week's pod has lots of updates! IMHOTEP: Pre-operative doses of pembrolizumab lead to significant pCR rates in dMMR colon cancer. https://doi.org/10.1200/JCO-25-02169 Real world rates of PJP suggest room for improvement in prophylaxis, especially those on corticosteroids + additional immunosuppressants. https://doi.org/10.1177/10600280261443794 Daraxonrasib given expanded access by FDA before approval: https://www.fda.gov/news-events/press-announcements/fda-permits-expanded-access-investigational-pancreatic-cancer-drug And yes, the ivermectin boom was real: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2848862 Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

    10 min
  7. Vepdegestrant

    7 mai

    Vepdegestrant

    The latest FDA drug approval is vepdegestrant, a heterobifunctional protein degrader, for ESR1 mutated breast cancer. We discuss what that actually means and some possible implications for clinical practice. Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

    12 min
  8. Targets Trop 2

    30 avr.

    Targets Trop 2

    This is our 1st in a series of podcasts/videos to role out once or twice a year on therapeutic targets in cancer. First up - Trop2 Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm Video with slides: https://youtu.be/mrDQyYkaF7A

    13 min
Tout afficher (432)

À propos

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

Informations

  • Création
    John Bossaer
  • Années d’activité
    2017 - 2026
  • Épisodes
    432
  • Classification
    Tous publics
  • Copyright
    © All rights reserved
  • Site web de l’émission
    OncoPharm

Vous aimeriez peut‑être aussi